Medicine guide
Rystiggo 280 mg/2 ml
As listed in the register: Rystiggo 280 mg/2 ml, solution injectable
280 mg/2 ml ·
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Rozanolixizumabum
- Made by
- UCB-Pharma SA
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- en association au traitement standard pour le traitement de la myasthénie auto-immune généralisée chez les patients adultes présentant des anticorps anti-récepteurs de l’acétylcholine (R-Ach) ou des anticorps anti-tyrosine kinase spécifique du muscle (MuSK).
From the official label · 2026-09-30 · Swissmedic
Details
| Made by | UCB-Pharma SA |
|---|---|
| Active substance | Rozanolixizumabum |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 280 mg/2 ml |
| Classification | L04AG16 · Cancer treatments and immune-system medicines |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Name in the register | Rystiggo 280 mg/2 ml, solution injectable |
| Packs | 1 Durchstechflasche(n) |
| Zulassungsnummer | 69227 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.